Life Sciences

Brownstein’s Life Sciences team of attorneys and public policy professionals helps pharmaceutical, medical device, biologics and genetics companies protect their ideas and increase their market share by providing comprehensive intellectual property, regulatory, corporate, policy, antitrust and business advice. They represent some of the world’s most innovative companies.

Representative Matters
  • Represented Fertility Lab Sciences, LLC in formation of a new fertility laboratory joint venture and intellectual property licensing arrangements in San Francisco.

  • Represented Fertility Lab Sciences, LLC in formation of a new fertility laboratory joint venture and intellectual property licensing arrangements in Northern Virginia.

  • U.S. Patent No. 7,744,893: T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same

  • Represented Fertility Lab Sciences, LLC in a joint venture transaction with Atlanta Center for Reproductive Medicine, LLC to form CCRM Atlanta, LLC.

  • Genetically modified mice having humanized TCR variable genes

  • Represented Colorado Center for Reproductive Medicine, one of Colorado’s leading fertility clinics, in a growth equity investment from TA Associates.

  • Genetically modified major histocompatibility complex animals

  • On behalf of a health care technology company, generated congressional support for client's efforts to partner with federal departments and agencies, which ultimately led to an opportunity with the Department of Veterans Affairs.

  • Mice expressing human voltage-gated sodium channels

  • Non-human animals with modifed immunoglobulin heavy chain sequences

  • U.S. Patent No. 7,972,848: Isolation and identification of cross-reactive T cells

  • Represented Fertility Lab Sciences in formation of a new fertility laboratory joint venture in Minneapolis, Minnesota.

  • Preserving consumer access to, and reducing incidents of abuse of, common ingredients in over-the-counter allergy and cold medications.

  • Represented medical device manufacturer for protection of stents, valves, and catheters.

  • Represented Breakthrough Products in its $3.4 million convertible note purchase agreement.

  • Co-lead counsel for a medical device manufacturer in a patent infringement action in S.D. Cal against primary competitor. Case settled right before Markman proceedings.

  • Brownstein represented Fertility Laboratories of Toronto, LLC in a joint venture transaction with Thomas Hannam Medicine Professional Corporation to establish Fertility Laboratories of Toronto Inc. and Fertility Surgical Centres of Toronto Inc.

  • Brownstein represented Fertility Lab Sciences, LLC in a joint venture formation transaction.

  • Represented a healthcare company in creating innovative new joint venture ownership structure for in vitro fertilization labs, leveraging best of breed technologies and best practices through licensing and management systems. Researched and created innovative corporate and business structure achieving business priorities while addressing competing requirements in areas of corporate, tax, insurance, consumer finance, and health care, including restrictions on corporate practice of medicine, fee splitting, self-referral, and anti-kickback.

  • Working with Congressional committees of jurisdiction to challenge the Food and Drug Administration to apply more accurate risk/benefit profiles to needed therapies for obesity. Secured the introduction of and support for federal legislation to provide reimbursement for these therapies under the Medicare and Medicaid programs.

  • Led the Coalition for Patient Safety and Medicine Integrity, a group of pharmaceutical, medical device and medical products companies, in developing the substance and strategy for passage of the SAFE DOSES Act, which modernized the criminal code to increase penalties for medical product cargo theft and provide law enforcement tools to deter and prosecute this criminal activity. At a time known for partisan gridlock in Congress, our Brownstein team successfully devised solutions for overcoming legislative paralysis, resulting in one of the few new laws enacted by the 112th Congress.

  • Represented Breakthrough Products, Inc. in their $3 million Series B equity financing.

  • Served as Nevada counsel to Apricus Biosciences, Inc. in connection with an underwritten public offering of common stock and warrants and issued opinions to the underwriters, the company and the company's transfer agent.

  • During the health care reform debate, helped a major pharmaceutical company successfully advocate for a new FDA-approval pathway for follow-on biologic treatments in a way that preserves the United States' competitive edge in biotechnology while ensuring an appropriate balance between investment in new discovery and containing costs to patients.

  • Worked on behalf of a small biopharmaceutical company to ensure new Medicaid rules would not make it cost-prohibitive to provide its rare-disease medicine to Medicare recipients.

  • On behalf of Z-Medica, a medical device company, worked to introduce the effectiveness of their product, QuikClot, to the military. QuikClot is now in widespread use in the military, in first responder and law enforcement units, and within various Homeland Security markets. The product is so effective that a military advisory committee recommended that all soldiers carry packets in their first-aid kits.

  • Served as local Nevada counsel to Apricus Biosciences, Inc., formerly known as Nexmed, Inc., in connection with the issue and sale of units consisting of common stock and warrants.

  • Represented Firehouse Ventures, LLC and its affiliates in the sale of all stock to VCA Animal Hospitals, Inc., a subsidiary of VCA Antech, Inc. Firehouse Ventures owned and operated six veterinary hospitals in the Denver metropolitan area.

  • Assisted Aion Partners LLC in its corporate structuring and private placement of limited liability company units to raise equity for bringing its technology to market. Brownstein also secured the intellectual property rights for Aion to sell its proprietary, green technology that minimizes the occurrence of hospital-acquired secondary infections.

  • Assisted a pharmaceutical company in obtaining appropriate reimbursement rates under new health reform law.

  • In Health Care Reform, aided a major pharmaceutical company in its successful fight to preserve patent protection for costly, research intensive, biological pharmaceutical products.

  • Rrepresented Firehouse Ventures, LLC, a veterinary practice roll-up organization, in general business and corporate advisory legal matters. Brownstein helped to form the company, guided the founders through several rounds of equity and debt financings, and have provided employment, ERISA and benefits advice including phantom stock plans. Brownstein also handles all of Firehouse Ventures' litigation, real estate and practice acquisitions.

  • Represented an artificial heart valve company in a $20 million supply contract dispute resulting in favorable mitigation of client exposure and the eventual sale of the company to a major healthcare conglomerate.

  • Negotiated two office leases in Boulder, Colorado for over 100,000 square feet of office and lab space on behalf of Gilead Sciences, a leading biopharmaceutical company.

Meet The Team

Emily K. Weber Shareholder T 303.223.1188 eweber@bhfs.com
Michael W. King Shareholder T 303.223.1130 mking@bhfs.com
Cate McCanless Policy Director T 202.747.0505 cmccanless@bhfs.com
Peter M. Goodloe Of Counsel T 202.747.0506 pgoodloe@bhfs.com
Alexander R. Dahl Shareholder T 202.747.0508 adahl@bhfs.com
Cara L. Crowley-Weber, Ph.D. Shareholder T 303.223.1145 ccrowley-weber@bhfs.com
Robert P. Attai Shareholder T 303.223.1271 rattai@bhfs.com
Kevin A. Cudney Shareholder T 303.223.1166 kcudney@bhfs.com
Martha L. Fitzgerald Shareholder T 303.223.1472 mfitzgerald@bhfs.com
Ryan J. Cudnik Of Counsel T 775.398.3813 rcudnik@bhfs.com
Sharon E. Caulfield Shareholder T (303) 223-1110 scaulfield@bhfs.com
Lisa Hogan Shareholder T 303.223.1185 lhogan@bhfs.com
Ishra K. Solieman Staff Attorney T 303.260.1880 isolieman@bhfs.com
Paul J. Prendergast, Ph.D. Shareholder T 303.223.1194 pprendergast@bhfs.com
Joshua A. Weiss Associate T 303-223-1268 jweiss@bhfs.com
Martine Tariot Wells Associate T 303.223.1213 mwells@bhfs.com
Brian M. McKeon Senior Policy Advisor T 202.872.5283 bmckeon@bhfs.com
Elizabeth A. Maier Policy Director T 202.872.5299 emaier@bhfs.com